Androgenic Alopecia
Conditions
Brief summary
This randomized, placebo-controlled, double-blind study evaluates the efficacy and tolerability of the allogeneic human adipose derived stem cell component extract on androgenic alopecia in relatively healthy adults. A total of 38 subjects received 1.2 g of allogeneic human adipose derived stem cell component extract per month or a placebo for 16 weeks.
Detailed description
This randomized, placebo-controlled, double-blind study evaluates the efficacy and tolerability of the allogeneic human adipose derived stem cell component extract on androgenic alopecia in relatively healthy adults. A total of 38 subjects received 1.2 g of allogeneic human adipose derived stem cell component extract per month or a placebo for 16 weeks. Hair count and thickness will be primary outcomes.
Interventions
OTHERstem cell component extract
The Allogeneic Human adipose derived stem cell component extract
Sponsors
Pusan National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to 59 Years
Healthy volunteers
Yes
Inclusion criteria
* androgenic alopecia basic and specific(BASP) classification: M2, C2, U1, V1, or F1 or higher
Exclusion criteria
* patient of scalp disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of total hair counts by phototrichogram | 16 weeks |
Outcome results
None listed